EGFR and non-small cell lung carcinoma: In summary, NSCLC patients harbored secondary BRAF V600E mutations because of acquired resistance to EGFR-TKI could benefit from the combination with EGFR-TKI (e.g., osimertinib) and FDA-approved two-drug therapy (e.g., dabrafenib, trametinib).